QIAGEN N.V.
About QIAGEN N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $2.1B
- Net income
- $424.9M
- Total assets
- $6.3B
- Market cap
- $7.6B
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $7.6B
- Dividend yield
- 0.97%
- Shares outstanding
- 208.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 28, 1996
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $424.9M in FY2025.
- Trading 35% below its 52-week high.
- Pays a dividend yielding about 0.97% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review QIAGEN N.V..
Write a review
News about QIAGEN N.V.
News & sentiment via Polygon.io
